SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

30 May 2026 Evaluate
The March 2026 quarter revenue stood at Rs. 18143.50 millions, up 10.74% as compared to Rs. 16384.40 millions during the corresponding quarter last year.The Total Profit for the quarter ended March 2026 of Rs. 2622.90 millions grew from Rs.-650.50 millionsOperating Profit saw a handsome growth to 4610.60 millions from 3800.80 millions in the quarter ended March 2026.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 18143.50 16384.40 10.74 73367.50 66779.20 9.87 73367.50 66779.20 9.87
Other Income 298.80 214.90 39.04 946.40 712.90 32.75 946.40 712.90 32.75
PBIDT 4610.60 3800.80 21.31 18749.30 15963.20 17.45 18749.30 15963.20 17.45
Interest 104.80 162.00 -35.31 435.10 630.40 -30.98 435.10 630.40 -30.98
PBDT 4201.60 823.40 410.27 18010.00 12517.40 43.88 18010.00 12517.40 43.88
Depreciation 703.10 651.90 7.85 2688.70 2519.70 6.71 2688.70 2519.70 6.71
PBT 3498.50 171.50 1939.94 15321.30 9997.70 53.25 15321.30 9997.70 53.25
TAX 875.60 822.00 6.52 3996.10 3490.10 14.50 3996.10 3490.10 14.50
Deferred Tax -65.50 63.00 -203.97 -25.10 81.10 -130.95 -25.10 81.10 -130.95
PAT 2622.90 -650.50 -503.21 11325.20 6507.60 74.03 11325.20 6507.60 74.03
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 25.41 23.20 9.54 25.56 23.90 6.91 25.56 23.90 6.91

Ipca Laboratories Share Price

1780.90 62.50 (3.64%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: